NCT00203424已完成2 期
A Phase II Trial of Adjuvant Bevacizumab and Erlotinib in Patients at High Risk for Early Relapse Following Radical Prostatectomy for Prostate Cancer
Translational Oncology Research International16 个研究点 分布在 1 个国家目标入组 23 人开始时间: 2006年1月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 23
- 试验地点
- 16
- 主要终点
- To Evaluate the Efficacy of Bevacizumab Plus Erlotinib
研究概览
简要总结
The purpose of this study is to evaluate the safety and effectiveness of bevacizumab plus erlotinib following radical prostatectomy.
详细描述
This study explores the anti-tumor activity of adjuvant bevacizumab plus erlotinib in a select group of prostate cancer patients deemed at high risk for early relapse following radical prostatectomy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Karnofsky performance status of > 80
- •Patients must have localized, organ-confined prostate cancer documented by physical examination, CT scan, or bone scan, and must have undergone radical prostatectomy. Post RP must have documented node negative prostate cancer.
- •Pretreatment granulocyte count > 1500/mm3, hemoglobin > 9.0 g/dL, and platelet count > 100,000/mm3,
- •Normal PT and PTT
- •Serum creatinine < 2.0 mg/dL
- •Adequate hepatic function with a serum bilirubin < upper limit of normal (ULN), AST and ALT < 1.5x ULN, and alkaline phosphatase < 2.5x ULN.
- •High-risk prostate cancer defined as a pre-RP prostate specific antigen level > 15 ng/dL or a Gleason score of > 8 or Stage T3 disease or positive surgical margins
- •Men of childbearing potential must be willing to consent to using effective contraception while on treatment and for 3 months thereafter
排除标准
- •Evidence of small cell (neuroendocrine) tumor
- •Evidence of metastatic disease
- •Prior administration of immunotherapy, biological therapy, hormonal therapy or radiation therapy for prostate cancer
- •Active secondary malignancies (other than basal cell carcinoma of the skin)
- •Serious, nonhealing wound, ulcer, or bone fracture.
- •Clinically significant cardiovascular disease (e.g., blood pressure of >150/100 mmHg, myocardial infarction, or unstable angina), New York Heart Association (NYHA) Grade II or greater congestive heart failure, serious cardiac arrhythmia requiring medication, or clinically significant peripheral vascular disease. Patients with a history of myocardial infarction or stroke within the last 6 months will be excluded.
- •Presence of seizures not controlled with standard medical therapy
- •Active infection requiring parenteral antibiotics at the time of the first administration of study drugs
- •Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 0, or anticipation of need for major surgical procedure during the course of the study; minor surgical procedures, fine needle aspirations or core biopsies within 7 days prior to Day
- •Current, recent (within the 4 weeks preceding Day 0), or planned participation in another experimental drug study
- •Inability to comply with the study visit and follow-up schedule or procedures
- •History of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that might affect the interpretation of the results of the study or render the subject at high risk from treatment complications.
- •Urine protein:creatinine ration > 1.0 at screening
- •Evidence of bleeding diathesis or coagulopathy.
- •History of abdominal fistula, gastrointestinal perforation, or intraabdominal abscess within 28 days prior to Day
- •Presence of central nervous system or brain metastases
研究组 & 干预措施
Erlotinib + Bevacizumab
Experimental
Participants received Erlotinib every day for 24 weeks and Bevacizumab every 3 weeks for a total of 8 doses
干预措施: Erlotinib + Bevacizumab (Drug)
结局指标
主要结局
To Evaluate the Efficacy of Bevacizumab Plus Erlotinib
时间窗: Determined by time to tumor recurrence, as measured by rising prostate specific antigen (PSA) after radical prostatectomy.
Time to Tumor Recurrence
时间窗: Tumor progression assessed every 3 months during Follow-up Period for a maximum of 3 years after administration of first study treatment
次要结局
- Overall Survival(Survival status was assessed every 3 months after completion of study treatment for a maximum of 3 years after administration of first study treatment)
- Time to Tumor Progression.(Tumor progression assessed every 3 months during Follow-up Period for a maximum of 3 years after administration of first study treatment)
研究者
研究点 (16)
Loading locations...
相似试验
已完成
2 期
Bevacizumab and Erlotinib Hydrochloride in Treating Patients With Metastatic or Unresectable Biliary TumorsCholangiocarcinoma of the Extrahepatic Bile DuctCholangiocarcinoma of the GallbladderGastrointestinal CancerRecurrent Extrahepatic Bile Duct CancerRecurrent Gallbladder CancerUnresectable Extrahepatic Bile Duct CancerUnresectable Gallbladder CancerNCT00356889National Cancer Institute (NCI)56
已完成
2 期
Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity CancerFallopian Tube CancerPrimary Peritoneal Cavity CancerRecurrent Ovarian Epithelial CancerStage IV Ovarian Epithelial CancerNCT00126542National Cancer Institute (NCI)35
已完成
2 期
Bevacizumab and Erlotinib in Treating Patients With Advanced Liver CancerAdult Primary Hepatocellular CarcinomaAdvanced Adult Primary Liver CancerLocalized Unresectable Adult Primary Liver CancerRecurrent Adult Primary Liver CancerNCT00365391National Cancer Institute (NCI)27
已完成
2 期
A Study to Test the Safety and Efficacy of Erlotinib Plus Bevacizumab to Treat Advanced Thymoma and Thymic CancerThymic CancerThymomaNCT00369889Indiana University School of Medicine18
终止
1 期
Study of Bevacizumab and Erlotinib for Patients With Hormone Refractory Prostate CancerProstate CancerNCT00996502Columbia University4